Sotatercept significantly reduced mortality risk by 85% in patients with PAH compared with placebo. The safety profile of sotatercept remained stable over 2.5 years, with manageable adverse events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback